Krystal Biotech Secures Crucial UK Approval for At-Home Genetic Therapy, Testing the Bull Case

Krystal Biotech (KRYS) secures UK MHRA approval for VYJUVEK, a genetic therapy for dystrophic epidermolysis bullosa. Explore the 12-year orphan exclusivity, at-home dosing benefits, and the financial bull vs. bear cases surrounding the company's revenue projections.